Altimmune
ALT
172 hedge funds and large institutions have $453M invested in Altimmune in 2024 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 29 closing their positions.
103% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 29
77% more call options, than puts
Call options by funds: $20.6M | Put options by funds: $11.6M
37% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 38
20% more funds holding
Funds holding: 143 → 172 (+29)
18.46% more ownership
Funds ownership: 64.32% → 82.78% (+18%)
16% more capital invested
Capital invested by funds: $389M → $453M (+$63.9M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$77.7M |
| 2 |
Millennium Management
New York
|
+$14.4M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$9.02M |
| 4 |
Rafferty Asset Management
New York
|
+$8.98M |
| 5 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$8.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$25.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.6M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$8.28M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$7.31M |
| 5 |
TIM
Timelo Investment Management
Aurora,
Ontario, Canada
|
-$5.24M |
ALT Hedge Fund Activity: Q1 2024 in Review
172 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2024, worth a combined $453M — up 16% from $389M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new ALT positions and 29 closed out — a net gain of 30 holders — while 52 added to existing stakes and 38 trimmed.
The largest buyer was State Street, adding an estimated $77.7M. The largest seller was Ameriprise, cutting an estimated $25.2M.
- 172 institutional investors held Altimmune (ALT) as of Q1 2024, up from 143 in Q4 2023.
- Funds reported $453M of Altimmune stock for Q1 2024, up 16% quarter-over-quarter.
- 59 funds opened new Altimmune positions in Q1 2024 and 29 closed out, a net change of +30 holders.
- The largest Altimmune buyer in Q1 2024 was State Street, an estimated $77.7M added.
- The largest Altimmune seller in Q1 2024 was Ameriprise, an estimated $25.2M sold.
Based on aggregated 13F filings for Q1 2024.